Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 257-268

  Narjoz, C ^a,b   Cessot, A ^b,c,d   Thomas Schoemann, A ^c,d,e   Golmard, J L ^f   Huillard, O ^b,c,d   Boudou Rouquette, P ^b,c,d   Behouche, A ^a   Taieb, F ^c,d   Durand, J P ^c,d   Dauphin, A ^c,d   Coriat, R ^b,d   Vidal, M ^c,d,e   Tod, M ^g,h   Alexandre, J ^b,c,d   Loriot, M A ^a,b   Goldwasser, F ^b,c,d   Blanchet, B ^c,d,e  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Centre d étude et de recours sur les inhibiteurs de l angiogénèse CERIA   (France)

^d Assistance Publique Hôpitaux de Paris Hôpital Cochin Service de Cancérologie Médicale ^*  (France)

^e CNRS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h UNIVERSITÉ DE LYON   (France)

Author keywords

Drug exposure; Efficacy; Lean body mass; Pharmacogenetics; Sunitinib; Toxicity

Indexed keywords

SUNITINIB; ABC TRANSPORTER; ABCB1 PROTEIN, HUMAN; ABCG2 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; INDOLE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; N DEETHYLSUNITINIB; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; STEROID RECEPTOR; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER PATIENT; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; AGED; BLOOD; BODY WEIGHT; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ATP-BINDING CASSETTE TRANSPORTERS; BODY WEIGHT; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PYRROLES; RECEPTORS, STEROID; TREATMENT OUTCOME;

EID: 84922003120     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0178-2     Document Type: Article

References (45)

1. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028-1043
2. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24:5601-5608
3. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124
4. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513
5. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329-1338
6. Pasqualetti G, Ricci S, Dardano A, Ferdeghini M, Del Tacca M, Monzani F (2011) The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature. Mini Rev Med Chem 11:746-752
7. Penot P, Bouaziz JD, Battistella M, Kerob D, Pagès C, Vilmer C, Basset-Seguin N, Madjessli N, Comte C, Farges C, Bagot M, le Maignan C, Lebbé C (2013) Stabilization of multiple metastatic epithelioid sarcoma under treatment with sunitinib malate. Br J Dermatol 168:871-873
8. Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N, Feldman D, George S, Hershman J, Lechner T, Potter A, Raymond E, Treister N, Wood L, Wu S, Bukowski R (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 16:543-553
9. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50:551-603
10. Houk BE, Bello CL, Kang D, Amantea M (2009) A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 15:2497-2506
11. Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH, Oncology ASoC (2012) Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 30:1553-1561
12. Mathijssen RH, Sparreboom A (2009) Influence of lean body weight on anticancer drug clearance. Clin Pharmacol Ther 85:23, author reply 24
13. Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B (2012) Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS One 7:e42875
14. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67:93-101
15. Gusella M, Toso S, Ferrazzi E, Ferrari M, Padrini R (2002) Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol 54:131-139
16. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK (2009) Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 27:3133-3140
17. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108:1034-1041
18. Mizuno T, Fukudo M, Terada T, Kamba T, Nakamura E, Ogawa O, Inui K, Katsura T (2012) Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics. Drug Metab Pharmacokinet 27:631-639
19. Mizuno T, Terada T, Kamba T, Fukudo M, Katsura T, Nakamura E, Ogawa O, Inui K (2010) ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann Oncol 21:1382-1383
20. Yu H, Steeghs N, Nijenhuis CM, Schellens JH, Beijnen JH, Huitema AD (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets. Clin Pharmacokinet 53:305-325
21. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 66:357-371
22. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M (2009) Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta 404:134-139
23. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F, Collaboration CKDE (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766-772
24. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B (2005) Quantification of lean bodyweight. Clin Pharmacokinet 44:1051-1065
25. McLeay SC, Morrish GA, Kirkpatrick CM, Green B (2012) The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 51:319-330
26. Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S (2013) Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 108:887-900
27. Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, Kawamoto S, Shimoyama R, Nishidate T, Furuhata T, Sasaki K, Hirata K, Nakamura Y (2009) Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 54:572-580
28. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH (2012) The new CYP3A4 intron 6 C>T polymorphism (CYP3A4∗22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet Genomics 22:373-380
29. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711-725
30. Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238-246
31. Schipani A, Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Rodríguez Novoa S, Cuenca L, Soriano V, Chierakul N, Saguenwong N, Chuchuttaworn C, Hoskins JM, Dvorak AM, McLeod HL, Davies G, Khoo S, Back DJ, Di Perri G, Owen A (2010) Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother 54:5242-5250
32. Zhang B, Xie W, Krasowski MD (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9:1695-1709
33. Morgan DJ, Bray KM (1994) Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet 26:292-307
34. Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150
35. van der Veldt AA, Eechoute K, Gelderblom H, Gietema J, Guchelaar HJ, van Erp NP, van den Eertwegh AJ, Haanen JB, Mathijssen RH, Wessels JA (2011) Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 17:620-629
36. van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H (2009) Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412
37. Sugiyama M, Fujita K, Murayama N, Akiyama Y, Yamazaki H, Sasaki Y (2011) Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug Metab Dispos 39:757-762
38. Diekstra M, Klümpen H, Lolkema M, Yu H, Kloth J, Gelderblom H, Schaik R, Gurney H, Swen J, Huitema A, Neeltje S, Mathijssen R (2014) Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics. Clin Pharmacol Ther 96:81-89
39. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui K, Katsura T (2013) Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 52:593-609
40. Kim HR, Park HS, Kwon WS, Lee JH, Tanigawara Y, Lim SM, Kim HS, Shin SJ, Ahn JB, Rha SY (2013) Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. Cancer Chemother Pharmacol 72:825-835
41. Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA (2013) Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol 18:1060-1069
42. Hutson TE, Bukowski RM, Rini BI, Gore ME, Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, Martell B, Matczak E, Motzer RJ (2014) Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma. Br J Cancer 110:1125-1132
43. Swales KE, Moore R, Truss NJ, Tucker A, Warner TD, Negishi M, Bishop-Bailey D (2012) Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc Res 93:674-681
44. Hagedorn KA, Cooke CL, Falck JR, Mitchell BF, Davidge ST (2007) Regulation of vascular tone during pregnancy: a novel role for the pregnane X receptor. Hypertension 49:328-333
45. Zopf D, Heinig R, Thierauch K, Dietrich C, Hafner F, Christensen O, Lin T, Wilhelm S, Radtke R (2010) Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites. AACR 101st Annual Meeting 2010 - Apr 17-21, 2010; Washington, DC:Abstract 1666 clinical cancer research 70